Citi lowered the firm’s price target on Caribou Biosciences (CRBU) to $6 from $30 and keeps a Buy rating on the shares. The firm updated models in the Smid-cap biotech space following the Q3 reports. Citi adjusted its launch timelines for Caribou ‘s three cell therapies in development, saying its prior timelines were too aggressive.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRBU: